American Society of Hematology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

List of Presentations

Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation–Positive Langerhans Cell Histiocytosis

Whitlock JA

  • Presentation # 3618 – Poster
    December 13, 2021 | 06:00 PM EST

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound